Cyclo Therapeutics Crescita futura

Future criteri di controllo 2/6

Si prevede che Cyclo Therapeutics aumenterà gli utili e i ricavi rispettivamente del 45.9% e 75.3% all'anno, mentre si prevede che l'EPS crescerà del 56% all'anno.

Informazioni chiave

45.9%

Tasso di crescita degli utili

56.0%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.3%
Tasso di crescita dei ricavi	75.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	27 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CYTH - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	15	-22	N/A	N/A	2
12/31/2025	1	-27	N/A	-24	3
12/31/2024	1	-22	N/A	-22	3
9/30/2024	1	-25	-23	-23	N/A
6/30/2024	1	-21	-18	-18	N/A
3/31/2024	1	-19	-18	-18	N/A
12/31/2023	1	-20	-16	-16	N/A
9/30/2023	1	-19	-15	-15	N/A
6/30/2023	1	-19	-14	-14	N/A
3/31/2023	1	-18	-15	-15	N/A
12/31/2022	1	-15	-15	-15	N/A
9/30/2022	2	-13	-15	-15	N/A
6/30/2022	2	-13	-15	-15	N/A
3/31/2022	1	-13	-15	-15	N/A
12/31/2021	2	-14	-15	-15	N/A
9/30/2021	1	-14	-15	-15	N/A
6/30/2021	1	-12	-14	-14	N/A
3/31/2021	1	-10	-12	-12	N/A
12/31/2020	1	-9	-9	-9	N/A
9/30/2020	1	-9	-8	-8	N/A
6/30/2020	1	-9	-8	-8	N/A
3/31/2020	1	-8	-7	-7	N/A
12/31/2019	1	-8	-7	-7	N/A
9/30/2019	1	-6	-5	-5	N/A
6/30/2019	1	-5	-4	-4	N/A
3/31/2019	1	-5	-4	-4	N/A
12/31/2018	1	-4	-3	-3	N/A
9/30/2018	1	-4	-3	-3	N/A
6/30/2018	1	-4	N/A	-3	N/A
3/31/2018	1	-4	N/A	-3	N/A
12/31/2017	1	-4	N/A	-3	N/A
9/30/2017	2	-3	N/A	-3	N/A
6/30/2017	2	-4	N/A	-3	N/A
3/31/2017	1	-5	N/A	-3	N/A
12/31/2016	2	-4	N/A	-3	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-4	N/A	-3	N/A
3/31/2016	1	-3	N/A	-2	N/A
12/31/2015	1	-3	N/A	-2	N/A
9/30/2015	1	-2	N/A	-1	N/A
6/30/2015	1	-1	N/A	-1	N/A
3/31/2015	1	-1	N/A	-1	N/A
12/31/2014	2	-1	N/A	-1	N/A
9/30/2014	1	0	N/A	0	N/A
6/30/2014	1	0	N/A	0	N/A
3/31/2014	2	0	N/A	1	N/A
12/31/2013	2	0	N/A	1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CYTH rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CYTH rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CYTH rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CYTH ( 75.3% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CYTH ( 75.3% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CYTH è previsto essere elevato tra 3 anni

Cyclo Therapeutics Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 12%

Consensus revenue estimates decrease by 29%, EPS upgraded

Consensus forecasts updated

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Consensus forecasts updated

Recent updates

New major risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo

Cyclo therapeutics to join Russell 2000 Index

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics Provides Business Update

First quarter 2021 earnings released: US$0.76 loss per share (vs US$2.18 loss in 1Q 2020)

Cyclo Therapeutics, Inc. Announces Design of Pivotal Phase 3 Study Evaluating Trappsol Cyclo in Niemann-Pick Type C1

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Independent Chairman recently bought US$81k worth of stock

Full year 2020 earnings released: US$5.59 loss per share (vs US$6.96 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Previsioni di crescita degli utili e dei ricavi